ANGPTL7 and glaucoma: Further tests are needed to find out which approach restores optimal vision in patients with ocular diseases: (1) a wild-type or surrogate gene (e.g., CRB1 or CRB2 to a CRB1-RP patient), (2) a shortened gene supplementation (e.g., miniCEP290580–1180), (3) neuroprotective factors (e.g., CNTF), (4) the delivery of antiangiogenic factors (e.g., sFLT1), or (5) disease pathway-modulation (e.g., ANGPTL7 in glaucoma), or (6) the introduction of a light-activated protein.